SCHEMBL15955652

SCHEMBL15955652

CCN(C(=O)C1CCNCC1)c1ccc(OC)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
HSP90AA1 P07900 1/20 0.48
TDP1 Q9NUW8 1/20 0.43
OPRM1 P35372 2/20 0.43
OPRD1 P41143 2/20 0.43
NCOA1 Q15788 1/20 0.43
NCOA3 Q9Y6Q9 1/20 0.43
EPHX2 P34913 1/20 0.42
TNKS O95271 3/20 0.42
TNKS2 Q9H2K2 3/20 0.42
PDK2 Q15119 1/20 0.41
POLB P06746 1/20 0.41
NR1H4 Q96RI1 2/20 0.41
KDM4E B2RXH2 2/20 0.40
HPGD P15428 1/20 0.40
MAPT P10636 1/20 0.40
TSHR P16473 1/20 0.40
HTT P42858 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6171439 0.87 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2TDP1OPRM1EPHX2
SCHEMBL6521921 0.80 HTR2C (0.43)
Hydrochloric Acid SCHEMBL3394146 0.79 HTR2C (0.44)
SCHEMBL7001870 0.77 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2TDP1EPHX2KDM4E
SCHEMBL3033986 0.76 OPRM1 (0.49) ALDH1A1SMN1; SMN2TDP1OPRM1OPRD1
SCHEMBL4598838 0.76 GPR88 (0.48) ALDH1A1HSP90AA1OPRM1HTT
SCHEMBL15955650 0.76 TNKS (0.48) ALDH1A1SMN1; SMN2OPRM1OPRD1NCOA1
Hydrochloric Acid SCHEMBL654026 0.76 CNR2 (0.48)
SCHEMBL8352070 0.75 HTT (0.40) ALDH1A1NR1H4HPGDTSHRHTT
SCHEMBL4683004 0.75 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2TDP1OPRM1OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170327512-A1 MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL SCRIPPS RESEARCH INST (US) 2017-11-16 US disclosed
US-20150376198-A1 MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-12-31 US disclosed
EP-2956441-A1 MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL The Scripps Research Institute (US) 2015-12-23 EP disclosed
WO-2014127350-A1 MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL THE SCRIPPS RESEARCH INSTITUTE (US) 2014-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150376198-A1 MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL AVPR2, AVPR1A, AVPR1B ALDH1A1 2890/4885SMN1; SMN2 4422/4885HSP90AA1 806/4885
US-20170327512-A1 MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL AVPR2, AVPR1A, AVPR1B ALDH1A1 2890/4885SMN1; SMN2 4422/4885HSP90AA1 806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.